Treat-and-extend regimen for management of neovascular agerelated macular degeneration: recommendations from the Hong Kong Retina Expert Panel

Authors

  • Ian YH Wong Eye Institute, The University of Hong Kong
  • Danny SC Ng Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong
  • Nicholas SK Fung Eye Institute, The University of Hong Kong
  • Yvonne Chan Department of Ophthalmology, United Christian Hospital, Hong Kong
  • Derek CY Chung Department of Ophthalmology, United Christian Hospital, Hong Kong
  • Mary Ho Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, Hong Kong
  • Callie KL Ko Department of Ophthalmology, Tung Wah Eastern Hospital, Hong Kong
  • Joy WY Leung Department of Ophthalmology, Tung Wah Eastern Hospital, Hong Kong
  • Shaheeda Mohammed Hong Kong Eye Hospital, Hong Kong
  • Helena PY Sin Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, Hong Kong
  • Heather HY Tang Department of Ophthalmology, United Christian Hospital, Hong Kong
  • Raymond LM Wong Hong Kong Eye Hospital, Hong Kong
  • Timothy YY Lai 2010 Eye & Cataract Centre, Tsim Sha Tsui, Hong Kong

Abstract

Antivascular endothelial growth factor (anti-VEGF) agents are a safe and effective treatment option for neovascular age-related macular degeneration (nAMD). However, undertreatment related to the costs and route of administration of anti-VEGF agents remains a common problem for nAMD patients. The treat-and-extend (T&E) regimen for nAMD has proven to balance clinical effectivity with reduced numbers of injections. However, implementation of the T&E regimen depends on the capacity and resources of clinics and patient compliance. To determine the optimal T&E regimen for Hong Kong, a panel of retina specialists was initiated by MediPaper Medical Communications Limited to discuss the benefits and hurdles in adopting the T&E regimen and to develop recommendations for patient selection based on clinical needs, dosing criteria, and dosing regimen. Key recommendations included selecting patients with only-eye or recurrence for the T&E regimen, pre-booking clinic appointments to reduce patient visits, communicating the T&E regimen with non-vitreoretinal physicians and trainees, extending the maximum dose interval to 16 weeks, and actively engaging patients in decision making.

Downloads

Published

2019-08-12

How to Cite

1.
Wong IY, Ng DS, Fung NS, Chan Y, Chung DC, Ho M, Ko CK, Leung JW, Mohammed S, Sin HP, Tang HH, Wong RL, Lai TY. Treat-and-extend regimen for management of neovascular agerelated macular degeneration: recommendations from the Hong Kong Retina Expert Panel. Hong Kong J Ophthalmol [Internet]. 2019Aug.12 [cited 2024Mar.2];23(1):15-9. Available from: https://hkjo.hk/index.php/hkjo/article/view/264

Issue

Section

Opinion

Most read articles by the same author(s)

1 2 3 > >>